language
Language
Englishchevron_right
attach_money
Currency
$USDchevron_right
dark_mode
Dark Mode
policy
Privacy Policy
gavel
Terms of Service
SNNSNN

$33.27

-0.20
arrow_drop_down0.60%
Current Market·update13 Nov 2025 15:32
Day's Range
33.2-33.37
52-week Range
23.69-38.79

Chart

Loading chart...

Performance

Key Stats

Next Earnings Date
Next Earnings TimeUnknown
Volume64.18K
Average Volume 30d657.55K

AI SNN Summary

Powered by LiveAI
💰
33.49
Valuation (P/E Ratio)
Higher than industry average, but justified by growth
📈
0.31
EPS Growth (YoY)
Positive earnings growth trend
Show More 🔒

AI Scoreboard

Powered by LiveAI
🔒

Overall Analysis

Buy
72

Smith & Nephew exhibits strong fundamental performance with a solid market position and consistent dividend payouts. While its valuation is reasonable, some technical indicators suggest a cautious short-term outlook. Thematic alignment with healthcare innovation and an aging global population provides long-term tailwinds.

Very Strong

Thematic

85

Smith & Nephew benefits from significant thematic tailwinds in healthcare, driven by an aging global population, increasing demand for minimally invasive procedures, and advancements in medical technology.

Strong

Fundamental

78

Smith & Nephew demonstrates robust financial health with consistent revenue generation, healthy gross margins, and a commitment to returning capital to shareholders via dividends. While profitability improved in the latest reporting period, the P/E ratio suggests current valuation reflects significant growth expectations.

Neutral

Technical

60

Smith & Nephew's stock is trading below key moving averages on shorter timeframes, suggesting a short-term bearish bias. However, longer-term technicals like the 1-day RSI show it in neutral territory, indicating a lack of strong immediate directional conviction.

FactorScore
Aging Population95
Medical Technology Innovation88
Healthcare Spending Growth80
Emerging Markets Penetration75
Competitive Landscape87
FactorScore
Valuation60
Profitability70
Growth75
Balance Sheet Health70
Cash Flow78
Dividend Yield65
FactorScore
Trend Analysis45
Momentum60
Volume Confirmation70
Support & Resistance65
Short-term Indicators50

AI Investing Checklist

Powered by LiveAI
thumb_up

Bullish Points (8)

Financial Health & Liquidity chevron_right

Strong Cash Position

The company maintained a healthy end cash position of $617 million in 2024Q4, with operating cash flow of $987 million in the same period.

Growth and Profitability chevron_right

Improving Net Margin

The net margin improved from 4.7% in 2023Q4 to 7.1% in 2024Q4, indicating enhanced profitability on revenue.

Show More 🔒
thumb_down

Bearish Points (8)

Debt Level and Coverage chevron_right

Increasing Debt Load

Total debt increased from $3.084 billion in 2023Q4 to $3.321 billion in 2024Q4, while free cash flow saw a significant drop from $608 million to $606 million in the same periods.

Technical Analysis chevron_right

Short-Term Weakness Indicated

Multiple moving averages on shorter timeframes (1m, 5m, 15m, 30m) are showing 'Sell' signals, with the 1-minute Hull Moving Average at 31.47 suggesting potential downside.

Show More 🔒

Calendar

March 2025

28

Ex-Dividend Date

May 2025

28

Next Dividend Date

August 2025

5

Next Earnings Date

EPS Est.
Revenue Est.

H: $

A: $

L: $

H: 1.53B

A: 1.52B

L: 1.51B

Profile

Employees (FY)17.3K
ISIN-
FIGI-

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. It operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.

Seasonals

2025
2024
2023
2022
2021

Price Target

33.15 USD

The 39 analysts offering 1 year price forecasts for SNN have a max estimate of 38.00 and a min estimate of 28.00.

Debt Level and Coverage

Debt
Free cash flow
Cash & equivalents

Financial Position Analysis

Assets
Liabilities

Ownership

Free Float shares
864M (197.37%)
Closely held shares
-426M (-97.37%)
438M
Free Float shares
864M (197.37%)
Closely held shares
-426M (-97.37%)

Capital Structure

Market cap
13.77B
Debt
3.32B
Minority interest
0.00
Cash & equivalents
619M
Enterprise value
16.48B

Valuation - Ratios

P/E
P/S

Revenue to Profit Conversion

Revenue
5.81B
COGS
1.76B
Gross Profit
4.05B
OpEx
3.19B
Operating Income
860M
Other & Taxes
448M
Net Income
412M

Balance Sheet

Total assets
Total liabilities
Liabilities to assets %

Income Statement

Revenue
Net Income
Net Margin

Cash Flow

Operating Cash Flow
Investing Cash Flow
Financing Cash Flow
Show More 🔒